
Mass General Brigham Ventures
Investment Team
Our team combines proven investment acumen with the scientific background necessary to analyze the risks and complexities of early-stage life science investing. Our expertise encompasses the range of venture financing, biomedical research, entrepreneurship, operational management, product development, and strategic partnering. The team works closely with Mass General Brigham’s extensive network of clinical and scientific experts to source opportunities and validate them as commercially viable concepts.
Alumni
Entrepreneurs in residence

David de Graaf
Mediar Therapeutics, Board of Directors

Barbara Fox
Tilos Therapeutics, Founding CEO
(Acquired by Merck)
​

Robert Millman
Ncontrol Therapeutics, Founding CEO
CoStim, Co-Founder, President
(Acquired by Novartis)

John Ripple
Brave Bio, Board of Directors

Ellen Sheets, MD
SeQure DX, Founding CEO

Bill Yelle
FireCyte Therapeutics, Founding CEO